The advanced drug delivery market experienced significant growth in 2023, reaching a value of USD 234.84 billion. Projections indicate that the market will expand to USD 375.86 billion by 2033, growing at a compound annual growth rate (CAGR) of 4.6% over the forecast period from 2023 to 2033.
Oral drug delivery systems were the leading segment in 2023, accounting for 48% of the market share. Controlled release technologies also played a pivotal role, securing 42% of the market.
North America dominated the market in 2023, holding 38% of the global share. However, Asia Pacific is anticipated to be the fastest-growing region, with a projected CAGR of 7.4%.
Download statistics of this report @ https://www.towardshealthcare.com/download-statistics/5113
In 2022, the World Health Organization reported approximately 630,000 deaths from HIV-related causes, emphasizing the urgent need for better treatments. Advanced drug delivery methods are emerging as a promising solution to manage infectious diseases like HIV, offering new ways to treat patients and improve their outcomes.
The advanced drug delivery market includes various technologies designed to deliver drugs or biologics into the body more precisely, efficiently, and with greater control. These systems aim to maximize the therapeutic effect of medications while minimizing side effects and improving patient adherence. They use techniques like nanotechnology, microencapsulation, targeted drug delivery, and controlled-release systems.
Advanced drug delivery plays a vital role in modern medicine for several reasons. One key benefit is the ability to target drugs directly to specific tissues or cells, enhancing the treatment’s effectiveness while reducing side effects. This targeted delivery leads to better results with fewer unwanted reactions. Additionally, controlled-release systems allow for longer-lasting effects of medications, meaning patients don’t need to take their doses as often, making it easier for them to stick to their treatment plans.
These systems also help minimize off-target effects, improving patient comfort and safety. By reducing side effects, the treatment process becomes more tolerable, contributing to a better overall experience for the patient. Furthermore, some drug delivery systems can improve the bioavailability of drugs, ensuring that a higher portion of the drug reaches its target, thereby optimizing its effectiveness.
Advanced drug delivery technologies also allow for more personalized treatments. These systems can be tailored to meet the specific needs of individual patients, enabling healthcare providers to develop more effective and customized treatment strategies. In conclusion, advanced drug delivery systems represent a major step forward in medicine, offering better efficacy, safety, patient compliance, and personalized care.
In March 2022, Corium, Inc. received approval from the U.S. Food and Drug Administration (FDA) for its ADLARITY (donepezil transdermal system). This treatment is designed for patients with mild to severe Alzheimer’s-type dementia and is one of the first patches to deliver a consistent dose of donepezil through the skin once a week.
In the same month, the FDA also approved the first generic version of Symbicort (budesonide and formoterol fumarate dihydrate) Inhalation Aerosol. This inhaler is used to treat two common lung conditions— asthma in patients aged six and older, and chronic obstructive pulmonary disease (COPD), which includes chronic bronchitis and emphysema.
Our Table of Content (TOC) covers key healthcare market segments, materials, technologies and trends—helping you navigate market shifts and make informed decisions: https://www.towardshealthcare.com/table-of-content/advanced-drug-delivery-market-sizing
Access exclusive insight now @ https://www.towardshealthcare.com/price/5113
We’ve prepared a service to support you. Please feel free to contact us at sales@towardshealthcare.com
Web: https://www.towardshealthcare.com
Visit Dental Specifics: https://www.towardsdental.com
Get the latest insights on industry segmentation with our Annual Membership: Get a Subscription
For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare
Kedrion Biopharma has announced that its human coagulation factor X concentrate, COAGADEX®, has been granted orphan drug designation by the… Read More
enecard PBF, a pioneer in pharmacy benefit facilitation, has announced a strategic partnership with DecisionRX, Inc., a leader in medication… Read More
In a high-stakes biotech industry where drug development can span over a decade, four small but determined biotech companies are… Read More
cell-free DNA and precision medicine, has officially announced the launch of the TEODOR trial (ABCSG 61), a groundbreaking phase 2,… Read More
The global interventional radiology market is witnessing rapid expansion, driven by advancements in minimally invasive procedures, rising demand for diagnostic… Read More
The global physical therapy market is valued at USD 28.06 billion in 2024, growing to USD 29.18 billion in 2025… Read More